Literature DB >> 10385400

Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells.

V C Russo1, G Rekaris, N L Baker, L A Bach, G A Werther.   

Abstract

Insulin-like growth factor (IGF) action in the brain is modulated by IGF-binding proteins (IGFBPs) whose abundance can be altered by other locally expressed growth factors. However, the mechanisms involved are unclear. We here employed the neuroblastoma cell line SK-N-MC as a model to define the mechanisms involved in modulation of IGFBPs in neuronal cells. Western ligand blotting analysis and immunoprecipitation of conditioned media (CM) from SK-N-MC cells showed that in these cells, as in the brain, the most abundantly expressed IGFBP was IGFBP-2. However, IGFBP-2 was barely detectable in CM from cells treated with basic fibroblast growth factor (bFGF) without a change in IGFBP-2 messenger RNA (mRNA) abundance. These CM contained specific IGFBP-2 proteolytic activity, resulting in two IGFBP-2 fragments of 14 and 22 kDa. The activity was inhibited by EDTA/phenylmethylsulfonyl fluoride or aprotinin. Competitive binding studies indicated that IGFBP-2 fragments had reduced binding affinity for IGF-I. bFGF induced IGFBP-3 mRNA and protein. Affinity cross-linking of [125I]IGF-I to neuroblastoma cell membranes followed by immunoprecipitation revealed a approximately 38 kDa [125I]IGF-I/IGFBP-2 complex. Cell surface-associated IGFBP-2 was also susceptible to bFGF-induced proteolysis, with the appearance of a single cross-linked 21-kDa complex with low affinity for IGF-I. These findings indicate that intact IGFBP-2 and the 14-kDa, but not the 22-kDa fragment, bind to the cell surface. Our data suggest that induction of IGFBP-2 proteolysis on neuronal cell surface is a novel mechanism whereby IGF availability is modulated by the local growth factor bFGF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385400     DOI: 10.1210/endo.140.7.6771

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  What's new in the IGF-binding proteins?

Authors:  Steven A Rosenzweig
Journal:  Growth Horm IGF Res       Date:  2004-10       Impact factor: 2.372

2.  The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton.

Authors:  Masanobu Kawai; Anne C Breggia; Victoria E DeMambro; Xinchun Shen; Ernesto Canalis; Mary L Bouxsein; Wesley G Beamer; David R Clemmons; Clifford J Rosen
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

3.  Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.

Authors:  Toshiro Migita; Tadahito Narita; Reimi Asaka; Erika Miyagi; Hiroko Nagano; Kimie Nomura; Masaaki Matsuura; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Seimiya; Yuichi Ishikawa
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

4.  Induction of Id-1 by FGF-2 involves activity of EGR-1 and sensitizes neuroblastoma cells to cell death.

Authors:  Giovanni Passiatore; Antonio Gentilella; Slava Rom; Marco Pacifici; Valeria Bergonzini; Francesca Peruzzi
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

5.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

Review 6.  IGFBP2: integrative hub of developmental and oncogenic signaling network.

Authors:  Tao Li; M Elizabeth Forbes; Gregory N Fuller; Jiabo Li; Xuejun Yang; Wei Zhang
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

Review 7.  The Role of Inflammation, Hypoxia, and Opioid Receptor Expression in Pain Modulation in Patients Suffering from Obstructive Sleep Apnea.

Authors:  Piotr Kaczmarski; Filip Franciszek Karuga; Bartosz Szmyd; Marcin Sochal; Piotr Białasiewicz; Dominik Strzelecki; Agata Gabryelska
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.